{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"40","upperLimit":"62","value":"52"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"}],"units":"Participants"}],"description":"Disease-free survival is calculated from date of registration to date of first documentation of relapse or death due to any cause. Patients last known to be alive are censored at date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Adjuvant Chemotherapy:\n\nCapecitabine, 1500 mg/m\\^2/day, PO, Every 12 hrs on Days 1-14 of each cycle; Gemcitabine hydrochloride, 1000 mg/m\\^2, IV, Days 1 \\& 8 of each cycle.\n\nChemoradiotherapy:\n\nCapecitabine, 1330 mg/m\\^2/day, PO, Every 12 hrs, 7 days per week beginning the first day of RT and finishing the last day of RT; Radiation (RT): 3-dimensional conformal radiation therapy - 4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 900 cGy during week 1 in 180 cGy fractions; intensity-modulated radiation therapy: 4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 5,250 cGy in 210 cGy/fraction for a total of 25 fractions.","id":"OG000","title":"Adjuvant Chemotherapy + Chemoradiotherapy"}],"paramType":"NUMBER","populationDescription":"Eligible and analyzable patients that received protocol treatment.","reportingStatus":"POSTED","timeFrame":"Up to 2 years from registration","title":"2-year Disease-free Survival in All Patients","type":"SECONDARY","unitOfMeasure":"percentage of participants"}